Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Mauriac

Showing results (31-40 of 90) with videos related to

Pageof 9
Sort By:
Bulletin Du Cancer|January 1, 1981
[Chemotherapy associating mitomycin C, thiotepa and vindesine in advanced breast cancers. Study of 100 cases (author's transl)]J Chauvergne, M Durand, R Brunet, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trialsL Mauriac, J E Pippen, J Quaresma Albano, et al.
British Journal of Cancer|October 1, 1996
pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patientsI Soubeyran, N Quénel, J M Coindre, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancerH Bonnefoi, L Biganzoli, L Mauriac, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|July 1, 1996
Breast cancer and in vitro fertilization. About 32 casesO Jourdain, A Avril, L Mauriac, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal womenL Mauriac, M Debled, M Durand, et al.
British Journal of Cancer|November 1, 1996
Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST piG MacGrogan, L Mauriac, M Durand, et al.
Breast Cancer Research and Treatment|June 27, 2003
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapyI Vergote, J F R Robertson, U Kleeberg, et al.
Revue Neurologique|January 1, 1985
[Hashimoto's thyroiditis and myoclonic encephalopathy. Pathogenic hypothesis]D Latinville, O Bernardi, J P Cougoule, et al.
Bulletin Du Cancer|January 1, 1981
[Contribution of drill-biopsies to pre-treatment investigation of breast adenocarcinomas (author's transl)]L Mauriac, J Wafflart, M Durand, et al.
Pageof 9

Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
Bulletin Du Cancer|January 1, 1981
[Chemotherapy associating mitomycin C, thiotepa and vindesine in advanced breast cancers. Study of 100 cases (author's transl)]J Chauvergne, M Durand, R Brunet, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trialsL Mauriac, J E Pippen, J Quaresma Albano, et al.
British Journal of Cancer|October 1, 1996
pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patientsI Soubeyran, N Quénel, J M Coindre, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancerH Bonnefoi, L Biganzoli, L Mauriac, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|July 1, 1996
Breast cancer and in vitro fertilization. About 32 casesO Jourdain, A Avril, L Mauriac, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal womenL Mauriac, M Debled, M Durand, et al.
British Journal of Cancer|November 1, 1996
Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST piG MacGrogan, L Mauriac, M Durand, et al.
Breast Cancer Research and Treatment|June 27, 2003
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapyI Vergote, J F R Robertson, U Kleeberg, et al.
Revue Neurologique|January 1, 1985
[Hashimoto's thyroiditis and myoclonic encephalopathy. Pathogenic hypothesis]D Latinville, O Bernardi, J P Cougoule, et al.
Bulletin Du Cancer|January 1, 1981
[Contribution of drill-biopsies to pre-treatment investigation of breast adenocarcinomas (author's transl)]L Mauriac, J Wafflart, M Durand, et al.
Pageof 9